Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.
2.

Inhibition of colon and breast carcinoma cell growth by interleukin-4.

Toi M, Bicknell R, Harris AL.

Cancer Res. 1992 Jan 15;52(2):275-9.

3.
4.
5.

Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect.

Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B.

J Pharmacol Exp Ther. 2002 Dec;303(3):1273-82. Erratum in: J Pharmacol Exp Ther. 2003 Nov;307(2):829. Ryan Yassir [corrected to Rayyan Yassir]. J Pharmacol Exp Ther. 2003 Jul;306(1):421. Ryann Yaser [corrected to Ryan Yassir].

6.

Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.

Shen Y, Du Y, Zhang Y, Pan Y.

Mol Med Rep. 2015 Jul;12(1):456-62. doi: 10.3892/mmr.2015.3406.

PMID:
25738757
7.

Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.

Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM.

Int J Oncol. 2007 Apr;30(4):785-92.

PMID:
17332916
8.

Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.

Jiang XP, Yang DC, Elliott RL, Head JF.

Anticancer Res. 2011 Sep;31(9):2899-906.

PMID:
21868536
9.

Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H.

Am J Pathol. 2003 Dec;163(6):2531-41.

10.

Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.

Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH Jr.

J Cell Physiol. 1995 Oct;165(1):212-21.

PMID:
7559803
11.

Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.

Thomas M, Monet JD.

J Clin Endocrinol Metab. 1992 Sep;75(3):865-70.

PMID:
1517379
13.

The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a]anthracene-DNA adduct formation in breast cancer cells.

Abbadessa G, Spaccamiglio A, Sartori ML, Nebbia C, Dacasto M, Di Carlo F, Racca S.

Int J Oncol. 2006 May;28(5):1131-40.

PMID:
16596229
14.

Regulation of inflammation- and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages.

Burnett GT, Weathersby DC, Taylor TE, Bremner TA.

Anticancer Res. 2008 Jul-Aug;28(4B):2093-9.

15.

Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.

Cancer Res. 2000 Jun 1;60(11):3081-7.

16.

Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.

Gooch JL, Lee AV, Yee D.

Cancer Res. 1998 Sep 15;58(18):4199-205.

18.
19.

Inhibition of PKC-Induced COX-2 and IL-8 Expression in Human Breast Cancer Cells by Glucosamine.

Chou WY, Chuang KH, Sun D, Lee YH, Kao PH, Lin YY, Wang HW, Wu YL.

J Cell Physiol. 2015 Sep;230(9):2240-51. doi: 10.1002/jcp.24955.

PMID:
25754990
20.

Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.

Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, Piazza GA, Xing WQ, Weinstein IB.

Breast Cancer Res Treat. 1998 Apr;48(3):195-203.

PMID:
9598866

Supplemental Content

Support Center